Trials / NCT04356716
Sildenafil for Treatment of Choroidal Ischemia
Completed Phase 2 Drug / neuroprotection
- Sponsor
- Columbia University
- Treatment
- Sildenafil; Standard of Care Sildenafil; Ocular Coherence Tomography-Angiography (OCT-A); Visual Acuity (VA)
- Gene
- Not stated
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- 22 participants
- Started
- 2014-11-11
- Main results expected
- 2020-02-18
- Results posted
- Yes
- Record last updated
- 2025-07-04
What the study is testing
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.
Where it runs
United States (1)
- Columbia University Medical Center, Edward Harkness Eye Institute, New York, New York